Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extens...

Por Tanaka, Yoshiya, Yamamoto, Kazuhiko, Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Eguchi, Katsumi, Watanabe, Akira, Origasa, Hideki, Shoji, Toshiharu, Miyasaka, Nobuyuki, Koike, Takao
Publicado no Mod Rheumatol (2014)

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis

Por Takeuchi, Tsutomu, Yamamoto, Kazuhiko, Yamanaka, Hisashi, Ishiguro, Naoki, Tanaka, Yoshiya, Eguchi, Katsumi, Watanabe, Akira, Origasa, Hideki, Kobayashi, Mariko, Shoji, Toshiharu, Togo, Osamu, Miyasaka, Nobuyuki, Koike, Takao
Publicado no Mod Rheumatol (2016)

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows i...

Por Atsumi, Tatsuya, Yamamoto, Kazuhiko, Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Tanaka, Yoshiya, Eguchi, Katsumi, Watanabe, Akira, Origasa, Hideki, Yasuda, Shinsuke, Yamanishi, Yuji, Kita, Yasuhiko, Matsubara, Tsukasa, Iwamoto, Masahiro, Shoji, Toshiharu, Okada, Toshiyuki, van der Heijde, Désirée, Miyasaka, Nobuyuki, Koike, Takao
Publicado no Ann Rheum Dis (2016)

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation:...

Por Atsumi, Tatsuya, Tanaka, Yoshiya, Yamamoto, Kazuhiko, Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Eguchi, Katsumi, Watanabe, Akira, Origasa, Hideki, Yasuda, Shinsuke, Yamanishi, Yuji, Kita, Yasuhiko, Matsubara, Tsukasa, Iwamoto, Masahiro, Shoji, Toshiharu, Togo, Osamu, Okada, Toshiyuki, van der Heijde, Désirée, Miyasaka, Nobuyuki, Koike, Takao
Publicado no Ann Rheum Dis (2017)